UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (602) 602
Book Chapter (13) 13
Patent (9) 9
Book / eBook (8) 8
Web Resource (8) 8
Publication (4) 4
Conference Proceeding (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
life sciences & biomedicine (347) 347
science & technology (347) 347
humans (302) 302
cardiovascular system & cardiology (266) 266
cardiac & cardiovascular systems (258) 258
abridged index medicus (217) 217
male (201) 201
female (197) 197
middle aged (187) 187
aged (162) 162
cardiology and cardiovascular medicine (105) 105
treatment outcome (103) 103
risk factors (96) 96
drug therapy (94) 94
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (92) 92
platelet aggregation inhibitors - therapeutic use (84) 84
heart attacks (82) 82
mortality (76) 76
cardiology (74) 74
angioplasty, balloon, coronary (73) 73
coronary heart disease (71) 71
peripheral vascular disease (71) 71
care and treatment (68) 68
angioplasty (63) 63
cardiovascular (62) 62
general & internal medicine (60) 60
transluminal angioplasty (60) 60
cardiac patients (58) 58
cardiovascular disease (57) 57
acute coronary syndromes (56) 56
clinical trials (56) 56
medicine, general & internal (56) 56
drug therapy, combination (55) 55
double-blind method (53) 53
heart attack (53) 53
anticoagulants - therapeutic use (52) 52
stents (52) 52
anticoagulants (51) 51
time factors (50) 50
recombinant proteins - therapeutic use (49) 49
follow-up studies (47) 47
myocardial infarction (46) 46
heparin - therapeutic use (44) 44
peptide fragments - therapeutic use (43) 43
coronary artery bypass (42) 42
myocardial infarction - mortality (42) 42
abciximab (41) 41
antibodies, monoclonal - therapeutic use (40) 40
immunoglobulin fab fragments - therapeutic use (40) 40
myocardial infarction - therapy (40) 40
prospective studies (40) 40
randomized controlled trials as topic (40) 40
coronary disease - therapy (39) 39
risk assessment (38) 38
analysis (37) 37
coronary vessels (37) 37
diabetes (36) 36
fibrinolytic agents - therapeutic use (36) 36
health aspects (36) 36
survival analysis (36) 36
myocardial infarction - drug therapy (35) 35
adult (34) 34
platelet aggregation inhibitors - adverse effects (34) 34
internal medicine (33) 33
percutaneous coronary intervention (33) 33
hemorrhage - chemically induced (31) 31
cardiovascular diseases (30) 30
clinical outcomes (30) 30
patient outcomes (30) 30
animals (29) 29
electrocardiography (29) 29
angioplasty, balloon, coronary - adverse effects (28) 28
multivariate analysis (28) 28
research (28) 28
platelet aggregation inhibitors - administration & dosage (27) 27
prognosis (27) 27
peptides - therapeutic use (26) 26
surgery (26) 26
anticoagulants - adverse effects (25) 25
diabetes mellitus (25) 25
eptifibatide (25) 25
thrombosis (25) 25
coronary angiography (23) 23
medical colleges (23) 23
myocardial infarction - etiology (23) 23
patients (23) 23
proportional hazards models (23) 23
aged, 80 and over (22) 22
incidence (22) 22
platelets (22) 22
retrospective studies (22) 22
acute coronary syndrome - therapy (21) 21
hirudins (21) 21
recombinant proteins - adverse effects (21) 21
ticlopidine - analogs & derivatives (21) 21
acute coronary syndrome - drug therapy (20) 20
angina, unstable - drug therapy (20) 20
blood platelets (20) 20
glycoproteins (20) 20
acute disease (19) 19
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 12/2016, Volume 375, Issue 26, pp. 2519 - 2529
BACKGROUND The cardiovascular safety of celecoxib, as compared with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), remains uncertain. METHODS... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Celecoxib - adverse effects | Naproxen - adverse effects | Ibuprofen - therapeutic use | Humans | Middle Aged | Male | Risk | Celecoxib - therapeutic use | Naproxen - therapeutic use | Cyclooxygenase 2 Inhibitors - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Arthritis - drug therapy | Cyclooxygenase 2 Inhibitors - therapeutic use | Intention to Treat Analysis | Kidney Diseases - chemically induced | Cardiovascular Diseases - mortality | Female | Aged | Cardiovascular Diseases - chemically induced | Ibuprofen - adverse effects | Gastrointestinal Diseases - chemically induced | Care and treatment | Safety and security measures | Naproxen | Ibuprofen | Dosage and administration | Arthritis | Celecoxib | Diagnosis | Cardiovascular diseases | Risk factors | Cardiovascular disease | Side effects | Nonsteroidal anti-inflammatory drugs | Pain management | Myocardial infarction | Fees & charges | Hemorrhage | Pain | Motivation | Analgesics | Safety | Drug dosages | Cerebral infarction | Statistical analysis | Anemia | Committees | FDA approval | Patients | Manuscripts | Rheumatoid arthritis | Collaboration | Osteoarthritis | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2012, Volume 366, Issue 1, pp. 20 - 33
In this trial, vorapaxar, a protease-activated–receptor 1 antagonist that inhibits thrombin-induced platelet activation, was not effective in reducing the... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Follow-Up Studies | Angioplasty | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Pyridines - adverse effects | Cardiovascular Diseases - mortality | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Pyridines - therapeutic use | Double-Blind Method | Receptor, PAR-1 - antagonists & inhibitors | Kaplan-Meier Estimate | Combined Modality Therapy | Lactones - adverse effects | Lactones - therapeutic use | Acute Coronary Syndrome - drug therapy | Intracranial Hemorrhages - chemically induced | Coronary Artery Bypass | Acute Coronary Syndrome - therapy | Aged | Hemorrhage - chemically induced | Antagonists (Biochemistry) | Drugs | Dose-response relationship (Biochemistry) | Dosage and administration | Product/Service Evaluations | Drug therapy | Coronary heart disease | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | Proteinase-activated receptor 1 | Thrombin | Cardiovascular disease | Hemorrhage | Bleeding | Investigations | Manuscripts | Ischemia | Blood platelets | Acute coronary syndromes | Research centers | Index Medicus | Abridged Index Medicus | Malalties cardiovasculars | Bypass cardiopulmonar | Medicaments | Bypass cardiopulmonary | Plaquetes sanguínies | Cardiovascular diseases
Journal Article
11/2007, ISBN 0470319380
Book
The New England journal of medicine, ISSN 1533-4406, 05/2017, Volume 376, Issue 20, pp. 1933 - 1942
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2006, Volume 355, Issue 21, pp. 2203 - 2216
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 2016, Volume 134, Issue 24, pp. 1918 - 1930
Journal Article
Chest, ISSN 0012-3692, 06/2008, Volume 133, Issue 6, pp. 340S - 380S
This chapter about the recognition, treatment, and prevention of heparin-induced thrombocytopenia (HIT) is part of the Antithrombotic and Thrombolytic Therapy:... 
fondaparinux | bivalirudin | argatroban | heparin-induced thrombocytopenia | IgG | low-molecular-weight heparin | unfractionated heparin | coumarin-induced necrosis | lepirudin | danaparoid | Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology
Journal Article